Nav: Home

When green means stop

March 22, 2017

Optogenetics, the approach to use light to control key processes, has revolutionized how researchers investigate cellular signaling pathways, cellular behavior and the function of large and interconnected tissues such as the brain. This highly successful combination of optics and genetics is powered by light-sensitive proteins, many of which have been engineered to bind to each other upon light stimulation. New research by scientists at the Institute of Science and Technology Austria (IST Austria) expands this optogenetic protein toolbox. In the study by the group of Harald Janovjak, driven by first author and PhD student Stephanie Kainrath, and colleagues at the Children's Cancer Research Institute in Vienna, published today in Angewandte Chemie, the authors demonstrate the release of binding when exposed to green light.

The application of light as a stimulus has allowed researchers to manipulate cellular behavior in defined spaces and real-time and thereby opened doors for new types of experiments. The method has, however, flourished in those cases where light-sensitive protein parts, called protein domains, responded to light by binding to each other. Binding activates signaling. To ensure that signaling remains turned on, the cells, tissues or animals under study need to stay in the light. But constant exposure to light carries risks: bleaching and toxic side effects of light are commonly observed.

Kainrath and colleagues offer a way out as they re-purposed light-sensitive domains that release their interaction in response to light. As a consequence, researchers can now leave their study object in the dark to induce signaling, and move it into light at a precise timepoint to interrupt signaling. First author Stephanie Kainrath explains the significance of the research: "Our work was inspired by the desire to imitate biological signals that are always on, such as those that drive the growth of certain cancers. With our new tool we can also rapidly switch off such signals. This allows for new approaches in both cell-based and animal studies."

The newly engineered tool is especially versatile as it responds to light in the green part of the visible light spectrum. This is possible as the re-purposed domains, called cobalamin (vitamin B12)-binding domains (CBDs), utilize Vitamin B12 for their light response. It was only recently realized that Vitamin B12 is not only essential for human body function but also used in bacteria as a light sensor. Kainrath and colleagues demonstrate the use of these domains by linking them to a vertebrate receptor protein called fibroblast growth factor receptor 1 (FGFR1). Normally a part of these receptor reaches to the outside of cell where it can capture fibroblast growth factors, causing two receptors to bind to each other and activate signaling on the inside of the cell. The engineered optogenetic FGFR1 proteins bind to each other in the dark via the CBDs and activate signaling. Only in green light, the binding is released and signaling stops.

Experiments in zebrafish embryos showcase the potential of this new approach for animal studies. Zebrafish embryos modified to produce the engineered receptor and kept in the dark show the same developmental defects as embryos in which signaling is always active, a situation that resembles human disorders. By contrast, embryos that were allowed to develop in green light were normal, without any developmental defects. For Martin Distel, co-author and group leader at the Children's Cancer Research Institute, Vienna, the receptor is a useful tool for addressing oncogene addiction, the Achilles heel of some cancers: "CBD mediated and green light-controlled dissociation of protein complexes is a useful asset in the optogenetic toolbox. For potential applications in cancer research one might think of oncogene addiction. Aberrant activation of signals such as those linked to FGFs can now be shut down rapidly and from the outside by light to investigate consequences on cell behavior."

Harald Janovjak and his group work in the new field of synthetic physiology, which tackles complex biological problems with the approach to "build it to understand it". Stephanie Kainrath joined IST Austria's PhD program in 2015. Having passed her qualifying exam in December 2016, Stephanie now pursues research for her doctoral degree in the group of Harald Janovjak.

Institute of Science and Technology Austria

Related Cancer Research Articles:

Blueprint to beat cancer launched today by World Cancer Research Fund (WCRF)
Overweight and obesity increase cancer risk. A new report published today by World Cancer Research Fund (WCRF), and presented at the European Congress on Obesity in Vienna, shows that overweight or obesity is a cause of at least 12 cancers, five more than WCRF findings a decade ago.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
UA Cancer Center research team explores anti-breast cancer properties of soy
Genistein, a major compound in soy foods, might aid in the proper functioning of a gene that can malfunction to cause breast cancer.
Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.
Cancer Research UK announces Grand Challenge teams to answer biggest questions in cancer
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
Leading cancer research organizations to host cancer immunotherapy conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.
Cancer Research UK boosts efforts to overcome deadliest cancer as rates climb
CANCER RESEARCH UK has tripled its investment in pancreatic cancer, one of the hardest cancers to treat, since launching its research strategy in 2014 according to new figures published today (Wednesday).
Children's Research Institute at UT Southwestern research garners Stand Up To Cancer grant
Dr. Hao Zhu, Assistant Professor of Children's Medical Center Research Institute at UT Southwestern, is one of 10 researchers in the nation to receive a Stand Up to Cancer grant to further his studies of a gene whose absence protects mice against liver cancer and promotes liver tissue regeneration in mammals.
More Cancer Research News and Cancer Research Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Accessing Better Health
Essential health care is a right, not a privilege ... or is it? This hour, TED speakers explore how we can give everyone access to a healthier way of life, despite who you are or where you live. Guests include physician Raj Panjabi, former NYC health commissioner Mary Bassett, researcher Michael Hendryx, and neuroscientist Rachel Wurzman.
Now Playing: Science for the People

#544 Prosperity Without Growth
The societies we live in are organised around growth, objects, and driving forward a constantly expanding economy as benchmarks of success and prosperity. But this growing consumption at all costs is at odds with our understanding of what our planet can support. How do we lower the environmental impact of economic activity? How do we redefine success and prosperity separate from GDP, which politicians and governments have focused on for decades? We speak with ecological economist Tim Jackson, Professor of Sustainable Development at the University of Surrey, Director of the Centre for the Understanding of Sustainable Propserity, and author of...
Now Playing: Radiolab

An Announcement from Radiolab